# Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

> **NCT00414076** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Leiomyosarcoma
- Uterine Neoplasm

## Interventions

- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00414076
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12-19
- **Primary completion:** 2017-07-13
- **Final completion:** 2017-07-13
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2018-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414076, "Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00414076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*